Cartesian Therapeutics (RNAC) Other Operating Expenses (2023 - 2025)

Cartesian Therapeutics (RNAC) has reported Other Operating Expenses for 3 consecutive years, with $56.7 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Other Operating Expenses rose 648.12% year-over-year to $56.7 million; the TTM figure through Mar 2026 stood at $56.7 million (up 648.12% YoY), while the FY2025 annual figure was $56.7 million, up 648.12% from the prior year.
• Other Operating Expenses grew to $56.7 million in Q4 2025 per RNAC's latest filing, from $7.6 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $56.7 million in Q4 2025 and bottomed at $710000.0 in Q4 2023.
• Historically, Other Operating Expenses has averaged $21.7 million across 3 years, with a median of $7.6 million in 2024.
• Annual changes were most pronounced in 2024 — Other Operating Expenses soared 967.46% — and 2025, when it surged 648.12%.
• Cartesian Therapeutics' Other Operating Expenses stood at $710000.0 in 2023, then jumped by 967.46% to $7.6 million in 2024, then soared by 648.12% to $56.7 million in 2025.
• Business Quant data shows RNAC's Other Operating Expenses at $56.7 million in Q4 2025, $7.6 million in Q4 2024, and $710000.0 in Q4 2023.